Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase

The prognosis of patients with chronic phase (CP) chronic myeloid leukemia (CML) has significantly improved due to the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, approximately 15‒20% of patients ultimately experience treatment failure due to resistance or intolerance...

Descripción completa

Detalles Bibliográficos
Autor principal: Choi, Eun-Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133857/
https://www.ncbi.nlm.nih.gov/pubmed/36891575
http://dx.doi.org/10.5045/br.2023.2023017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133857/
https://www.ncbi.nlm.nih.gov/pubmed/36891575
http://dx.doi.org/10.5045/br.2023.2023017

Ejemplares similares